Through a major health platform exclusive collaboration with Marius Pharmaceuticals and more, the company is expanding access to innovative testosterone treatments
Hims & Hers Health, the leading health and wellness platform, announced the launch of a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.
An estimated twenty million men in the U.S. struggle with low testosterone. Left untreated, it can drain energy, dull mood and sexual desire, and raise risks of heart disease, diabetes, and cancer. Treatment can restore energy, improve sexual function, build muscle and bone strength, and support long-term health. Yet most never receive care due to stigma, outdated treatments, and high costs. Hims & Hers is changing that.
Health Technology Insights: Molina Nevada Awards $150K Grant to Expand Reno Health Access
In 2026, Hims & Hers will expand its category offerings with the launch of an exclusive branded oral testosterone through a major health platform exclusive collaboration with Marius Pharmaceuticals, a leader in testosterone therapy innovation. KYZATREX is a needle-free FDA-approved medication shown to restore testosterone levels in up to 96% of men. It also doubles free testosterone, the type of testosterone linked to energy, drive, and performance, all while maintaining a low side effect profile.
“Low testosterone care has been stuck in the past, stigmatized, expensive, and inaccessible for most men,” said Andrew Dudum, founder and CEO of Hims & Hers. “We’re bringing it into the future with treatments that are easy to access and designed around each individual. This isn’t just about one product, it’s about addressing a condition that fundamentally changes how millions of men will feel and show up in life, and about building an entirely new model of care that they can finally rely on.”
Health Technology Insights: Nuvig Therapeutics Names Woodhouse CEO, Mackay Board Chair
“Marius developed KYZATREX to modernize testosterone replacement therapy with an oral treatment backed by rigorous science and FDA approval,” said Shalin Y. Shah, CEO of Marius Pharmaceuticals. “Partnering with Hims & Hers allows us to bring this innovation to scale. Their platform has proven reach, accessibility, and trust with millions of customers, making them the perfect partner to expand access to KYZATREX and redefine what’s possible in men’s hormone health.”
Starting today, providers will also be able to prescribe tailored doses of compounded enclomiphene through the Hims & Hers platform and, for men experiencing sexual symptoms, offer personalized testosterone care that combines enclomiphene and tadalafil in a single dual-action treatment. Enclomiphene restores natural testosterone production, without compromising fertility, and has been shown to double testosterone levels. Customers begin with a simple at-home blood test, receive results in days instead of months, and then work with a licensed provider to find the treatment plan that best fits their needs.
Hims & Hers will also introduce access to injectable testosterone treatments in 2026, giving men even more options for care, all connected through the Hims & Hers digital platform with licensed providers and 24/7 access to support.
Health Technology Insights: Tempus Validates PurIST for Pancreatic Cancer Treatment
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
